NCT03072121

Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization

Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 440 (estimated)
• Sponsor: Jun Li · Academic / Other
• Sex: All
• Age: 45 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether Shexiang Baoxin Pill is effective in the treatment of coronary artery disease not amenable to revascularization on the basis of western medicine therapy.

Detailed description

The western medicine treatment for CAD not amenable to revascularization is limited. Shexiang Baoxin Pill, a kind of Chinese patent medicine has been used for treating coronary artery disease in clinical practice in China for many years. Shexiang baoxin pill(SBP) is applicable to "Qi deficiency and blood stasis syndrome" in traditional Chinese medicine. Recent experimental research has indicated that SBP can improve myocardial ischemia and promote therapeutic angiogenesis.

Conditions

• Coronary Artery Disease(CAD)

Interventions

Type	Name	Description
DRUG	Shexiang Baoxin pill	Conventional western medicine \& shexiang baoxin pill
DRUG	SBP placebo	Conventional western medicine \& placebo (for shexiang baoxin pill)
DRUG	Aspirin Enteric-coated Tablets	100mg tablet, one tablet daily.
DRUG	Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet	one tablet daily. (for patients who can't use aspirin)
DRUG	Atorvastatin Calcium	10 mg tablet, two tablets each night.
DRUG	Isosorbide Mononitrate Tab 20 MG	1 tablet two times daily.
DRUG	Metoprolol Tartrate Tab 25 MG	12.5 mg or 25 mg two times daily.
DRUG	Trimetazidine Dihydrochloride Tablets	20 mg tablet, one tablet three times daily.

Timeline

• Start date: 2017-06-01
• Primary completion: 2018-12-01
• Completion: 2019-02-01
• First posted: 2017-03-07
• Last updated: 2017-04-04